Oridion Microstream(R) Technology to be Incorporated Into Market Leader's Patient-Controlled Analgesia (PCA) Device
JERUSALEM and NEEDHAM, Massachusetts, January 15 /PRNewswire-FirstCall/ -- Oridion Systems Ltd. (SIX Swiss Exchange: ORIDN) today announced an agreement with a global healthcare company that is a market leader in medication infusion systems. Under this agreement, Oridion's Capnostream(TM) carbon dioxide (CO2) monitor using Microstream(R) capnography technology will be incorporated into a PCA infusion device at a future date, allowing hospital patients to control the flow of their pain medication within specified limits.
By enabling connectivity between the Capnostream and PCA device, clinicians will be able to monitor their patients' end tidal (CO2) levels. Clinicians using Microstream are more likely to detect respiratory depression than clinicians monitoring with pulse oximetry alone.(1) This is particularly important when administering potent pain medication.
The ability to monitor CO2 levels is vital. It can alert clinicians to episodes of hypoventilation as well as help them assess ventilation and treatment of asthma and chronic obstructive pulmonary disease (COPD) in patients. This is the reason why organizations, such as the Anesthesia Patient Safety Foundation (APSF)(2) and the American Society of Anesthesiologists (ASA)(3) recommend ventilatory monitoring when administering opiates and during procedural sedation. Patient-controlled analgesia systems are used in both environments.
"More and more hospital systems are becoming proactive about instituting policies to assure patient safety when potent drugs are used," said Gerry Feldman, president of Oridion. "It is good to see that the hospital community recognizes the importance of monitoring ventilation effectively, a necessity to safely eliminate unnecessary patient pain, a Joint Commission mandate. Our newest partner has selected Oridion, the world-wide leader in capnography monitoring, as an additional important step in their commitment to help hospitals reduce medication errors, improve patient safety and adhere to best clinical practices."
Further details regarding this agreement were not disclosed.
About Oridion
Oridion Systems Ltd. (http://www.oridion.com) is a global medical device company specializing in patient safety monitoring. The Company operates through wholly owned subsidiaries in the United States, Europe, and Israel.
Oridion develops proprietary medical devices and patient interfaces, based on its patented Microstream(R) technologies, for the enhancement of patient safety through the monitoring of the carbon dioxide (CO2) in a patient's breath. These products provide effective, proven airway management and are used in various clinical environments, including procedural sedation, pain management, operating rooms, critical care units, post-anesthesia care units, emergency medical services, transport, alternate care and other settings where patients' ventilation may be compromised and at risk.
(1) Jonathan B. Waugh, PhD, RRT, RPFT; Yulia Khodneva, MD; Chad A. Epps, MD, Monitoring to Improve Ventilation Safety during Sedation and Analgesia. Society for Technology in Anesthesia 2008.
(2) Anesthesia Patient Safety Foundation (APSF) Newsletter, Winter 2006-2007, Vol. 21, 4.
(3) American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology. 2002; 96(4):1004-17.
CONTACT: For further Oridion information please contact: Alan Adler,
Chairman and Chief Executive Officer, Walter Tabachnik, Chief Financial
Officer, Elena Gerberg, Investor Relations; e-mail: investor@oridion.com ,
website: http://www.oridion.com , phone: +972-2-589-9159, address: Oridion
Systems Ltd., P.O. Box 45025, 91450 Jerusalem, Israel.